NEW YORK, Aug. 17, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Sage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 24, 2024, Sage announced that it will no longer advance its oral experimental therapy SAGE-324 for essential tremor following a failure in a mid-stage trial. Citing topline data from its KINETIC 2 Phase 2 trial, Sage said SAGE-324 didn’t generate statistically significant results for the primary endpoint from baseline to Day 91. Additionally, there were no statistically significant differences between SAGE-324 doses and placebo over the same period for the primary endpoint, which took into account a clinical metric designed to measure tremor in the upper limb. As for the drug’s tolerability, Sage said there was a relationship between SAGE-324 and treatment-emergent adverse events (“TEAEs”) related to the central nervous system as well as TEAE frequency.
On this news, Sage’s stock price fell $2.70 per share, or 20.64%, to close at $10. 38 per share on July 24, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
